Compare TG & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TG | MOBI |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 366.1M |
| IPO Year | 1994 | 2026 |
| Metric | TG | MOBI |
|---|---|---|
| Price | $8.22 | $13.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 141.1K | 94.5K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.06 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $800,821,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.47 | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $6.25 | $12.66 |
| 52 Week High | $10.53 | $14.40 |
| Indicator | TG | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | N/A |
| Support Level | $7.54 | N/A |
| Resistance Level | $8.65 | N/A |
| Average True Range (ATR) | 0.28 | 0.00 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 92.76 | 0.00 |
Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.